APA (7th ed.) Citation

Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D., John, T., . . . Jänne, P. A. (2018). Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology, 36(9), 841. https://doi.org/10.1200/JCO.2017.74.7576

Chicago Style (17th ed.) Citation

Ramalingam, Suresh S., et al. "Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer." Journal of Clinical Oncology 36, no. 9 (2018): 841. https://doi.org/10.1200/JCO.2017.74.7576.

MLA (9th ed.) Citation

Ramalingam, Suresh S., et al. "Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer." Journal of Clinical Oncology, vol. 36, no. 9, 2018, p. 841, https://doi.org/10.1200/JCO.2017.74.7576.